Moreover, we intend to evaluate the number of dopaminergic neurons in the substantia nigra in mice with induced Parkinson’s disease and the concentration of dopamine, to assess the degree of α-synuclein and tau-protein aggregation in the brain of mice, as well as to assess the pharmacokineics of U-573 in the body of experimental animals. This evidence concerns the gene MAPT and Parkinson disease.